Varenicline combined with oral nicotine replacement therapy and smartphone-based medication reminders for smoking cessation: Feasibility randomized controlled trial

This study examined the effects of varenicline alone or in combination with oral nicotine replacement therapy, each given with or without smartphone medication reminders, on pharmacotherapy adherence and smoking abstinence in 34 adults enrolled in a smoking cessation program. The primary endpoint was self-reported and biochemically verified smoking abstinence. Biochemical confirmation of self-reported abstinence was defined as a breath CO level of ≤6 ppm, with in-clinic readings obtained using the Vitalograph BreathCO device.